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Article summary point 
Using whole-genome sequencing, in two UK hospitals, patients with diarrhea, toxigenic 
Clostridium difficile, but a negative fecal toxin result, were potential sources for 3% of 
infections; toxin-positive cases were potential sources for 10%, and another 6% were linked 
to both groups.  
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Abstract  
 
Background 
The role of symptomatic patients who are toxigenic strain-positive (TS+) but fecal toxin-
negative (FT-) in transmission of Clostridium difficile is currently unknown. 
 
Methods 
We investigated the contribution of symptomatic TS+/FT- and TS+/FT+ patients in C. difficile 
transmission in two UK regions. From two-step testing, all glutamate dehydrogenase (GDH)-
positive specimens, regardless of fecal toxin result, from Oxford (April2012-April2013) and 
Leeds (July2012-April2013) microbiology laboratories underwent culture and whole-genome 
sequencing (WGS), using WGS to identify toxigenic strains. Plausible sources for each 
TS+/FT+ case, including TS+/FT- and TS+/FT+ patients, were determined using WGS, with 
and without hospital admission data. 
 
Results 
1447/12772(11%) fecal samples were GDH-positive, 866/1447(60%) contained toxigenic C. 
difficile and fecal toxin was detected in 511/866(59%), representing 235 Leeds and 191 
Oxford TS+/FT+ cases. TS+/FT+ cases were three times more likely to be plausibly acquired 
from a previous TS+/FT+ case than a TS+/FT- patient. 51(19%) of 265 TS+/FT+ cases 
diagnosed >3 months into the study were genetically-related (≤2 single nucleotide 
polymorphisms) to ≥1 previous TS+/FT+ case or TS+/FT- patient: 27(10%) to only TS+/FT+ 
cases, 9(3%) to only TS+/FT- patients, and 15(6%) to both. Only 10/265(4%) were 
genetically-related to a previous TS+/FT+ or TS+/FT- patient and shared the same ward 
simultaneously or within 28 days. 
 
Conclusions 
Symptomatic TS+/FT- patients were a source of C. difficile transmission, although they 
accounted for less onward transmission than TS+/FT+ cases.  Although transmission from 
symptomatic patients with either fecal toxin status accounted for a low overall proportion 
of new cases, both groups should be infection control targets. 
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Background  
Clostridium difficile infection (CDI) remains a significant concern for patients and healthcare 
providers, despite recent falls in incidence in some settings, including the UK.[1] Three UK 
studies using whole-genome sequencing (WGS) have shown, in endemic settings with 
routine infection control policies, only a minority of cases are acquired from other, known, 
cases: 35% of cases in Oxford[2] and Leeds[3], and 37% of ribotype-027 cases in Liverpool[4] 
were genetically-linked to a previous case. Only a subset of these cases also shared time on 
the same hospital ward. Studies using other genotyping techniques have found similar 
results.[5-7] Such findings question the sources of C. difficile responsible for most CDIs.  
 
While hospitalized asymptomatically colonized patients are a potential source,[7-9] another 
group of patients with enhanced potential to transmit C. difficile are symptomatic patients 
who are toxigenic-strain positive (TS+), but fecal toxin negative (FT-).  These patients are 
identified by two-step algorithms for CDI diagnosis.[10] An initial screen (e.g. glutamate 
dehydrogenase (GDH) enzyme immunoassay (EIA), or toxin gene nucleic acid amplification 
test [NAAT]) detects the presence of C. difficile; the second confirmatory step detects fecal 
toxin using either EIA or a cell cytotoxin assay (CCT). In the UK TS+/FT- patients are usually 
regarded as being colonized with C. difficile but not infected, based on a large multi-center 
prospective study showing only patients with detectable fecal toxin had adverse 
outcomes.[11] However, outside the UK, such patients, typically identified with NAATs, are 
often,[12] but not universally,[13] regarded as having CDI, and NAAT testing has been 
recommended in some guidelines.[14] Resolving the disease state of TS+/FT- patients is not 
a focus of this study; instead we investigated their contribution to onward transmission of C. 
difficile. 
 
We undertook WGS of consecutive C. difficile GDH-positive fecal samples, irrespective of the 
subsequent fecal toxin assay result, in two UK centers, over 9-12 months. WGS, combined 
with hospital admission and ward movement data, were used to assess the contribution of 
C. difficile TS+/FT- and TS+/FT+ patients to onward transmission. 
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Methods 
Samples and setting 
Consecutive hospital and community samples submitted for C. difficile diagnostic testing 
were obtained from the microbiology laboratories of 2 UK teaching hospitals following the 
introduction of two-step testing: Leeds Teaching Hospitals, serving Leeds (population 
750,000, 07-July-2012 to 06-April-2013), and Oxford University Hospitals, serving 
Oxfordshire (population 600,000, 01-April-2012 to 31-March-2013). In Leeds and Oxford, 
repeat samples from the same patient ≤14 and ≤28 days, respectively, following a toxin-
positive sample were not routinely processed. Patient admissions and hospital ward 
movements were obtained from hospital administration systems. Inclusion of community 
samples allowed cases diagnosed in the community, but potentially acquired in hospital, to 
be identified. 
 
In Leeds, any patient with ≥1 episode of unexplained diarrhea was isolated and a fecal 
sample sent for C. difficile testing. TS+/FT+ cases were isolated for the duration of hospital 
admission. Ward staff could isolate TS+/FT- patients if they were considered a transmission 
risk. In Oxford, patients with unexplained diarrhea (≥3 unformed stools in 24 hours) were 
isolated and treated empirically with oral vancomycin. TS+/FT+ cases remained isolated 
until 48 hours following resolution of diarrhea. Treatment and isolation were discontinued 
in TS+/FT- patients unless clinical suspicion of CDI remained high. 
 
Diagnostic testing and WGS 
Leeds samples were tested with GDH EIA, C. diff Chek (Techlab, Blacksburg, VA), and when 
GDH-positive an in-house cell cytotoxicity assay, and Oxford samples with Premier C. difficile 
GDH and GDH-positive samples with Premier Toxins A&B EIA (Meridian Bioscience, 
Cincinnati, OH). At both centers, GDH-positive samples were cultured as described 
previously[15] and whole-genome sequenced using Illumina technology. In Leeds, isolates 
were confirmed as C. difficile with MALDI-TOF mass-spectrometry; in Oxford WGS was used. 
Sequences were mapped to the 630 reference genome[16], and assembled de novo[17] (see 
Supplementary Methods for details). Multi-locus sequence types, STs,[15] were determined 
in silico. 
 
 
6 
 
 
 
Toxigenic strains were identified using BLAST searches of de novo assemblies (≥1000 
nucleotide identities with toxin A or B genes). Non-toxigenic strains were excluded (n=249, 
most common STs ST15(n=66,27%), ST26(n=66,27%), ST7(n=51,20%), and ST3(n=11,4%); the 
remainder were recognized non-toxigenic STs).  
 
Definitions 
Patients with toxigenic C. difficile were classified according to fecal toxin result: as TS+/FT+ 
and TS+/FT-. In patients diagnosed with more than one C. difficile strain, as defined by WGS 
(see below), each was considered separately. Some patients had several samples with the 
same strain, and could be consistently fecal toxin-negative, consistently toxin-positive, or 
have both fecal toxin-negative and toxin-positive samples. Each TS+/FT+ CDI’s origin was 
determined using standard surveillance definitions.[18] Cases were defined as healthcare-
associated if sampled >48 hours after admission or discharged within ≤4 weeks, as 
indeterminate if discharged 4-12 weeks previously, and as community-associated if 
discharged >12 weeks prior to sampling, or without any hospital admission. 
 
Analysis 
Single nucleotide polymorphisms (SNPs) between sequences were determined from 
maximum likelihood phylogenies constructed with phyML[19] after correction for 
recombination with ClonalFrameML.[20] Sequences related to a previous sequence within 
≤2 SNPs were considered consistent with plausible direct transmission; ≤2 SNPs is expected 
between transmitted strains obtained ≤123 days apart.[2] Results for sequences related to 
previous sequences within varying thresholds (0-10 SNPs) were generated as a sensitivity 
analysis. In patients with multiple samples, sequences >10 SNPs different to a previous 
sequence from the same patient were considered to represent acquisition of a new strain; 
10 SNPs is considerably more variation than would be expected from within-host diversity 
and mutation over the one year study period.[2]  
 
Where the only possible genetically-related sources of a TS+/FT+ case were TS+/FT- 
patients, the origin was attributed to TS+/FT- patients; similarly, if all possible genetically-
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related sources were TS+/FT+ cases, the origin was attributed to TS+/FT+ cases. Where a 
TS+/FT+ case was genetically-linked to either a TS+ patient with both fecal toxin-positive 
and toxin-negative samples, or several patients including ≥1 TS+/FT+ case and ≥1 TS+/FT- 
patient, the origin was denoted as either a TS+/FT+ case or TS+/FT- patient. 
 
Patients with toxigenic C. difficile who shared time on the same ward following the 
diagnosis of the first patient and before the diagnosis of the second were considered to 
have had ward contact. Patients admitted to the same ward, but up to 28 days apart, were 
considered related by possible ward contamination if the first patient was diagnosed before 
their ward discharge, and the second patient following their admission to the same ward.[5] 
Patients who shared time in the same hospital, but had no ward or ward contamination 
contact, were considered to have hospital contact. A sensitivity analysis assumed ward 
contamination persisted for 365 days. 
 
Logistic regression was used to test for associations between ST and the proportion of 
TS+/FT+ cases genetically-related to a previous TS+/FT+ case or TS+/FT- patient, for the 9 
most common STs (all with ≥10 cases). 
 
Ethics 
The study was approved by the Berkshire Research Ethics Committee (10/H0505/83) and 
the Health Research Authority (8-05(e)2010). 
 
Results 
8068 hospital and community samples were submitted for C. difficile testing in Leeds, and 
4704 samples in Oxford. 771(10%) and 637(14%) samples were GDH-positive respectively, 
and, of these, 488(63%) and 372(58%) contained toxigenic C. difficile by WGS (Figure 1). 
Leeds samples were obtained from 367 patients (220 female,60%), median (interquartile 
range, IQR) 72(52-82) years old, representing 382 genetically distinct 
infections/colonizations, and Oxfordshire samples from 297 patients (167 female,56%), 
78(62-86) years old, 302 genetically distinct infections/colonizations. 
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In both laboratories, 59% of samples containing toxigenic C. difficile had fecal toxin detected 
despite using different assays, EIA in Oxford (218/372) and CCT in Leeds (289/488). These 
samples represented 235 distinct TS+/FT+ cases in Leeds, with 3.7 healthcare-
associated/indeterminate cases per 10000 bed-days and 7.9 community-associated cases 
per 100000 person-years, and 191 distinct TS+/FT+ cases in Oxfordshire, 3.2/10000 bed-
days and 7.0/100000 person-years, respectively (Figure 1). 
 
There was considerable genetic diversity amongst the C. difficile causing the 426 TS+/FT+ 
cases, with 52 different STs identified. The 10 most frequently isolated STs (common 
ribotype equivalents) accounted for 285(67%) of cases, and were (in rank order) 
ST2(014/020), ST8(002), ST6(005), ST11(078), ST10(015), ST5(023/069), ST44(015), 
ST3(001/072), ST14(014), ST17(018). The epidemic ST1(027/NAP1) strain was only found in 
three (Leeds) cases.  
 
Genetic relationships between infections/colonizations 
Samples were compared with all prior samples from the same center over the study 
periods, but potential sources were sought only for new TS+/FT+ infections from 3 months 
into the study at each center (Leeds n=142, Oxfordshire n=123), to ensure sufficient time for 
their possible sources to have been sampled. Using a threshold of ≤2 SNPs to determine 
genetic relatedness, overall 51/265(19.2%, 95%CI, 14.7-24.5%) TS+/FT+ cases were 
genetically-related to ≥1 sequenced previous TS+/FT+ case or TS+/FT- patient (Table 1). 
9/265(3.4%, 1.6-6.3%) of TS+/FT+ cases were genetically linked only to TS+/FT- patients and 
not to previous TS+/FT+ cases. In contrast, 27/265(10.2%, 6.8-14.5%) TS+/FT+ cases were 
genetically linked to other TS+/FT+ cases, and 15/265(5.7%, 3.2-9.2%) to both TS+/FT+ cases 
and TS+/FT- patients. There was no evidence of a difference in sources between Leeds and 
Oxford (Table 1; exact p=0.27).  
 
Considering the source of C. difficile for all patients, TS+/FT- patients as well as TS+/FT+ 
cases, results were similar (Table S1; exact p=0.85 comparing all patients vs. TS+/FT+ cases 
alone): 75/433(17%) patients could be linked to a previously sequenced TS+/FT+ case or 
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TS+/FT- patient, 16(4%) to only TS+/FT- patients, 36(8%) to only previous TS+/FT+ cases and 
23(5%) to both.  
 
There were 13 ST44 infections, none of which were genetically-related to a prior TS+/FT+ 
case, the remaining 8 most common STs were compared with all other STs as the reference 
group. Within the limits of the relatively small numbers of TS+/FT+ cases within each ST, 
there was no evidence that CDI caused by any of these STs were more or less likely, to be 
genetically-related to a previous TS+/FT+ case or TS+/FT- patient (p≥0.18; Table 2), or that 
CDI source was associated with patient age, sex or healthcare/community-associated 
disease (Table 3). 
 
Over the whole study period at both centers, considering all 684 TS+/FT+ cases and TS+/FT- 
patients, 535 were not related to any other TS+/FT+ case or TS+/FT- patient within ≤2 SNPs. 
The remaining 149 TS+/FT+ cases and TS+/FT- patients were clustered: sequences included 
in a cluster were related to ≥1 other sequence within ≤2 SNPs in the cluster, but not 
necessarily to all of them. Most clusters contained 2 or 3 patients; 14(9%) patients were in 
clusters consisting of exclusively TS+/FT- patients, 45(30%) were in exclusively TS+/FT+ 
clusters, and 90(60%) were in clusters with both TS+/FT- patients and TS+/FT+ cases (Figure 
3). 
 
Epidemiological relationships between genetically-related infections/colonizations 
Only a subset of TS+/FT+ cases and plausible TS+/FT+ or TS+/FT- sources related within ≤2 
SNPs shared a hospital-based epidemiological link. Considering all 265 TS+/FT+ cases from 
both Leeds and Oxfordshire from 3 months into the study, 27(10%) were genetically-related 
to only previous TS+/FT+ cases. However, only 6(2%) were genetically-related and shared 
time on the same ward. A further 4(2%) were genetically-related and were inpatients on the 
same ward at different times within 28 days. 8(3%) were not admitted to the same ward 
within 28 days, but were admitted to the same hospital at the same time (Table 1).  
 
Another 9(3%) TS+/FT+ cases were genetically-related to only previously TS+/FT- patients: 
5(2%) sharing time on a ward, 1(0.4%) the same ward at different times within 28 days, and 
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1(0.4%) time in the same hospital as above. There was a trend towards potential TS+/FT- 
sources being more likely to share time on the same ward as the subsequent TS+/FT+ case, 
compared with potential TS+/FT+ sources (5/9 vs. 6/27, exact p=0.10). An additional 15(6%) 
TS+/FT+ cases were genetically-related to both a TS+/FT- patient and a TS+/FT+ case, but 14 
had no hospital-based links with the genetically-related sources, suggesting these patients 
may share a common indirect source rather than direct hospital-based contact. No 
additional epidemiological links between genetically-related TS+/FT+ cases and TS+/FT+ 
cases or TS+/FT- patients were identified if ward contamination could persist for up to 365 
days. 
 
To test the robustness of our observations to the SNP threshold used to define plausible 
direct transmission, the number of TS+/FT+ cases genetically-related to a previous TS+/FT+ 
case or TS+/FT- patient within varying SNP thresholds from 0 to 10, and any associated 
hospital-based epidemiological links, were determined (Figure 3). As expected, as the 
number of SNPs used to define plausible direct transmission increased, the percentage of 
TS+/FT+ cases genetically-related to a previous TS+/FT+ or TS+/FT- patient increased. 
However, the number of TS+/FT+ cases genetically-related and with plausible 
epidemiological contact, i.e. sharing hospital wards, remained relatively constant from 2 
SNPs onwards, supporting the 2 SNP threshold used for the main analysis. 
 
Discussion 
We used WGS and ward admission data to investigate the proportion of CDI cases 
potentially acquired from symptomatic patients with toxigenic C. difficile, but with no 
detectable fecal toxin. TS+/FT+ CDI cases were three times more likely to be genetically-
related to a previous TS+/FT+ case (27/265) than a TS+/FT- patient (9/265). Considering the 
subset of potential sources that also shared time on the same ward, or were admitted to 
the same ward within 28 days, i.e. the most probable of the genetically-plausible 
transmission events, CDI cases were 1.7 times more likely to be related to a previous 
TS+/FT+ case compared with a TS+/FT- patient (10/265 vs. 6/265). However, this finding 
could be explained by the observation that the overall ratio of TS+/FT+ to TS+/FT- cases in 
the study was also 1.7. This suggests that the rate of transmission, on a per patient basis, 
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from each TS+/FT+ or TS+/FT- patient is likely to be very similar. By contrast, 
asymptomatically colonized patients are likely less infectious. Using national databases and 
a transmission model, individual hospitalized CDI cases have been estimated to transmit C. 
difficile at a rate 15 (95%CI 7.2-32) times that of hospitalized asymptomatically colonized 
patients.[21] However, as asymptomatic carriage is more common than CDI (e.g. 8-fold in 
hospitals[9]), colonized patients, as a group, could still account for a substantial amount of 
transmission. In a Canadian study, isolation of all asymptomatically colonized patients 
reduced CDI incidence by 62% compared with historic controls.[9] 
 
The overall number of our TS+/FT+ CDI cases potentially attributable to the combination of 
TS+/FT+ cases and TS+/FT- patients with diarrhea was low: 19% of TS+/FT+ CDI cases were 
genetically-related to a previous TS+/FT+ or TS+/FT- patient, only 6% also shared a hospital 
ward at the same time or within 28 days, and only 10% had any form of hospital contact. 
This supports previous WGS-based studies, at both our hospitals[2,3] and others[4], that 
found that only a minority of CDIs are acquired from other cases in endemic settings. The 
proportion in the present study is lower than the 35-37% identified previously. The most 
likely explanation is the very small number of infections with the epidemic ST1(027/NAP1) 
strain, reflecting falling UK incidence[22,23], and the burden of transmissions attributable to 
ST1 in previous studies.[3] 
 
Our study has several limitations. Only patients with diarrhea were sampled, and at the 
discretion of individual practitioners. However, the ratio of toxin-positive stools sequenced 
to samples tested was 3.6%(289/8068) in Leeds, and 4.6%(218/4704) in Oxford, suggesting 
rates of testing were high, including compared with the UK average from 2008 of 6.45%, 
when testing was principally based on toxin detection.[24]  Of those tested, some patients 
with C. difficile will have been missed by the GDH assay (sensitivity 92.3-97.1%[11,25]). In 
addition, 2.6% of isolates failed WGS and were excluded. We therefore may have missed 
some links between TS+/FT- or TS+/FT+ patients and TS+/FT+ CDI cases, modestly 
underestimating the frequency with which this occurs.[5] However, if cases were missed at 
random, we believe the relative amount of transmission attributable to TS+/FT+ cases and 
TS+/FT- patients has been robustly estimated. We did not gather data on factors that might 
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influence a TS+/FT- patient’s potential to transmit C. difficile, including duration and severity 
of diarrhea, antibiotic exposure, or the timing and duration of isolation. In addition, 
systematic serial sampling was not undertaken to allow an assessment of the duration of 
detectable C. difficile. Our study was performed in a setting where the majority of CDI arises 
from a diverse range of endemic strains; findings may vary in higher incidence settings, 
including where the epidemic ST1(027/NAP1) strain dominates. 
 
Despite these limitations, we demonstrate that patients with toxigenic C. difficile without 
detected fecal toxin account for a quarter or more of potential within hospital transmission 
events from symptomatic patients. More intensive infection control interventions around 
such cases, including routine isolation, should be considered to mitigate transmission risk. 
Compared with asymptomatically colonized patients, TS+/FT- patients represent a good 
initial target for expanding infection control efforts, as they are less numerous, and, as 
discussed above, appear more infectious[21] on a per patient basis. However, ultimately if 
the findings of [9] can be replicated, isolation of asymptomatically colonized patients, who 
are each less infectious, but more numerous, may result in greater reductions in 
transmission. Substantially greater resource requirements limit the later approach. Some 
GDH-positive fecal toxin-negative patients may carry non-toxigenic C. difficile and not pose 
an infection control risk. Patients with toxigenic C. difficile could be identified by screening 
with a toxin gene NAAT, or using a three-step strategy (GDH-positive, fecal toxin-negative 
samples tested with a toxin gene NAAT).  
 
The results of this and previous studies in both Oxford and Leeds suggest CDI cases, and also 
symptomatic patients with toxigenic C. difficile with a negative fecal toxin result, are not 
sources for the majority of CDI. Major unanswered questions remain, including what 
proportion of CDI cases can be explained by healthcare-associated and community contact 
with asymptomatically colonized people, and the extent to which other possible sources 
including food[26,27] and the environment[28] contribute to CDI. In addition to reducing 
the risk of CDI through antimicrobial stewardship,[23] understanding the relative 
importance of each of these reservoirs across a range of settings is required to develop 
rational control polices and reduce the incidence of CDI. Meanwhile, efforts to reduce 
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hospital transmission from symptomatic patients with toxigenic C. difficile with a negative 
fecal toxin result should be implemented. 
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Tables 
 
  Epidemiological links between genetically linked cases, 
   No. (% n, % genetically linked) 
Possible transmission source Genetically 
linked ≤2 
SNPs (% n) 
Shared time 
on same ward 
Shared same 
ward within 28 
days 
Shared time in 
same hospital only 
Leeds (CDI cases, n = 142)         
Prior TS+/FT+ cases 17 (12) 2 (1, 12) 2 (1, 12) 7 (5, 41) 
TS+/FT- patients 5 (4) 2 (1, 40) 1 (1, 20) 1 (1, 20) 
Both 11 (8) 0 (0, 0) 0 (0, 0) 1 (1, 9) 
Total 33 (23) 4 (3, 12) 3 (2, 9) 9 (6, 27) 
Oxford (CDI cases, n = 123)     
Prior TS+/FT+ cases 10 (8) 4 (3, 40) 2 (2, 20) 1 (1, 10) 
TS+/FT- patients 4 (3) 3 (2, 75) 0 (0, 0) 0 (0, 0) 
Both 4 (3) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Total 18 (15) 7 (6, 39) 2 (2, 11) 1 (1, 6) 
Combined (CDI cases, n = 265)         
Prior TS+/FT+ cases 27 (10) 6 (2, 22) 4 (2,15) 8 (3, 30) 
TS+/FT- patients 9 (3) 5 (2, 56) 1 (1, 11) 1 (1, 11) 
Both 15 (6) 0 (0, 0) 0 (0, 0) 1 (1, 7) 
Total 51 (19) 11 (4, 22) 5 (2, 10) 10 (4, 20) 
 
Table 1. Proportion of toxigenic strain-positive, fecal toxin-positive (TS+/FT+) CDI cases 
genetically (≤2 SNPs) and epidemiologically related to prior TS+/FT+ cases and TS+/FT- 
patients. 
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  Genetically-related to prior TS+/FT+ case or TS+/FT- patient 
ST n Total (% n) Odds ratio (95% CI) P value 
All other STs 114 24 (21) 1 - 
2 33 9 (27) 1.41 (0.58, 3.42) 0.45 
5 17 4 (24) 1.15 (0.34, 3.86) 0.82 
6 23 2 (9) 0.36 (0.08, 1.63) 0.18 
8 21 3 (14) 0.63 (0.17, 2.30) 0.48 
10 14 1 (7) 0.29 (0.04, 2.32) 0.24 
11 20 5 (25) 1.25 (0.41, 3.78) 0.69 
14 10 3 (30) 1.61 (0.39, 6.69) 0.51 
44 13 0 (0) - - 
 
 
Table 2. Association between ST and proportion of CDI cases genetically-related to prior 
TS+/FT+ cases and TS+/FT- patients. Each ST in the table was compared to all other STs (the 
reference group) by logistic regression. 
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No 
genetically 
linked 
source 
TS+/FT-
source 
TS+/FT+ 
source Both 
p 
value 
p value, any source 
vs no genetically-
linked source 
Classification (row %)     0.99 0.83 
Community-
associated 
53 (83%) 1 (2%) 7 (11%) 3 (5%)   
Indeterminate 22 (85%) 1 (4%) 2 (8%) 1 (3%)   
Healthcare-
associated 
139 (79%) 7 (4%) 18 (10%) 11 (6%)   
Age     0.76 0.59 
Median 75 82 79 78   
IQR 54 - 83 69 - 86 24 - 85 58 - 84   
Sex (row %)     0.5 0.35 
Female  115 (79%) 4 (3%) 17 (12%) 10 (7%)   
Male 98 (84%) 5 (4%) 9 (8%) 5 (4%)   
 
Table 3. Patient demographics according to CDI source (n=265). Age and sex were not 
recorded for 2 patients.  Exact p values are shown for classification and sex; p values for age 
were calculated with the Kruskal-Wallis rank test. 
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Figure legends 
 
Figure 1. Samples and patient demographics for Leeds (panel A) and Oxfordshire (panel B). 
Each percentage uses the row above as denominator. Distinct infection is one >10 SNPs 
distinct to any previous infection in the same patient. HA, healthcare-associated. CA, 
community-associated. MALDI-TOF MS, matrix assisted laser desorption time of flight mass 
spectrometry. Age and sex were not recorded for 3 Oxfordshire patients. 
 
Figure 2. Numbers of patients in clusters related within ≤2 SNPs. Clusters consisting 
exclusively of toxigenic strain-positive, fecal toxin-negative (TS+/FT-) patients are shown in 
blue, clusters consisting exclusively of TS+/FT+ cases in red, and clusters with both TS+/FT- 
patients and TS+/FT+ cases in orange. 
 
Figure 3. Proportion of Leeds and Oxfordshire CDI cases genetically-related to a previous 
toxigenic strain-positive, fecal toxin-positive (TS+/FT+) case or TS+/FT- patient within 
varying SNP thresholds. Bars are shaded according to the fecal toxin status of the 
genetically-related potential sources of infection.  
 
